{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:44:07Z","timestamp":1791323047643,"version":"4.3.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s11033-020-05481-9","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T09:02:53Z","timestamp":1589533373000},"page":"4699-4708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":129,"title":["Molecular mechanism of action and pharmacokinetic properties of methotrexate"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4238-0676","authenticated-orcid":false,"given":"V.","family":"Maksimovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Pavlovic-Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vukmirovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cvejic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mooranian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Al-Salami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Golocorbin-Kon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"5481_CR1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/1756-185X.12862","volume":"19","author":"AN Malaviya","year":"2016","unstructured":"Malaviya AN (2016) Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story. Int J Rheum Dis 19:844\u2013851","journal-title":"Int J Rheum Dis"},{"key":"5481_CR2","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nrrheum.2016.175","volume":"12","author":"PM Brown","year":"2016","unstructured":"Brown PM, Pratt AG, Isaacs JD (2016) Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol 12:731\u2013742","journal-title":"Nat Rev Rheumatol"},{"key":"5481_CR3","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD (2016) Preventing and managing toxicities of high-dose methotrexate. Oncologist 21:1471\u20131482","journal-title":"Oncologist"},{"key":"5481_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10637-005-4541-1","volume":"24","author":"J Walling","year":"2006","unstructured":"Walling J (2006) From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 24:37\u201377","journal-title":"Invest New Drugs"},{"key":"5481_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/00000441-195102000-00009","volume":"221","author":"R Gubner","year":"1951","unstructured":"Gubner R, August S, Ginsberg V (1951) Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 221:176\u2013182","journal-title":"Am J Med Sci"},{"key":"5481_CR6","first-page":"16","volume":"124","author":"M Weinblatt","year":"2013","unstructured":"Weinblatt M (2013) Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc 124:16\u201325","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"5481_CR7","doi-asserted-by":"publisher","DOI":"10.5937\/pomc17-24188","author":"V Maksimovi\u0107","year":"2020","unstructured":"Maksimovi\u0107 V, Golo\u010dorbin-Kon S, Mikov M, Cveji\u0107 J, Pavlovi\u0107 Popovi\u0107 Z, Vukmirovi\u0107 S (2020) New horizons of methotrexate application. PONS Med J. https:\/\/doi.org\/10.5937\/pomc17-24188","journal-title":"PONS Med J"},{"key":"5481_CR8","first-page":"41","volume":"48","author":"S Ka\u0161ikovi\u0107 Le\u010di\u0107","year":"2011","unstructured":"Ka\u0161ikovi\u0107 Le\u010di\u0107 S, Pavlovi\u0107 Popovi\u0107 Z, Zvezdin B, Kukavica D (2011) Sarkoidoza u trudno\u0107i i postpartalnom period. Pneumon 48:41\u201346","journal-title":"Pneumon"},{"key":"5481_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.12703\/P6-89","volume":"6","author":"M Judson","year":"2014","unstructured":"Judson M (2014) Advances in the diagnosis and treatment of sarcoidosis. F1000Prime Rep 6:89","journal-title":"F1000Prime Rep"},{"key":"5481_CR10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/MCP.0b013e3283642a7a","volume":"19","author":"JP Cremers","year":"2013","unstructured":"Cremers JP et al (2013) Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med 19:545\u2013561","journal-title":"Curr Opin Pulm Med"},{"key":"5481_CR11","unstructured":"https:\/\/www.stopsarcoidosis.org\/wp-content\/uploads\/FSR-Physicians-Protocol1.pdf. Accessed 03 Mar 2020"},{"key":"5481_CR12","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1136\/thx.54.8.742","volume":"54","author":"R Baughman","year":"1999","unstructured":"Baughman R, Lower E (1999) A clinical approach to the use of methotrexate for sarcoidosis. Thorax 54:742\u2013746","journal-title":"Thorax"},{"key":"5481_CR13","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1001\/archinte.1995.00430080088011","volume":"155","author":"E Lower","year":"1995","unstructured":"Lower E, Baughman R (1995) Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 155:846\u2013851","journal-title":"Arch Intern Med"},{"key":"5481_CR14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.5603\/PiAP.2014.0069","volume":"82","author":"A Goljan-Geremek","year":"2014","unstructured":"Goljan-Geremek A et al (2014) Methotrexate as a single agent for treating pulmonary sarcoidosis: a single centre real-life prospective study. Pneumonol Alergol Pol 82:518\u2013533","journal-title":"Pneumonol Alergol Pol"},{"key":"5481_CR15","doi-asserted-by":"publisher","DOI":"10.3614\/svdld.v36i3.8449","author":"C Fang","year":"2019","unstructured":"Fang C, Zhang Q, Wang N, Jing X, Xu Z (2019) Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: a single center real-world study. Sarcoidosis VDLD. https:\/\/doi.org\/10.3614\/svdld.v36i3.8449","journal-title":"Sarcoidosis VDLD"},{"key":"5481_CR16","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2015.PA843","author":"I Vizel","year":"2015","unstructured":"Vizel I, Vizel A (2015) Methotrexate as a single agent for the treatment of patients with progressive pulmonary sarcoidosis. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.congress-2015.PA843","journal-title":"Eur Respir J"},{"key":"5481_CR17","first-page":"60","volume":"17","author":"RP Baughman","year":"2000","unstructured":"Baughman RP, Winget DB, Lower EE (2000) Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 17:60\u201366","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"5481_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/00000441-199003000-00002","volume":"299","author":"EE Lower","year":"1990","unstructured":"Lower EE, Baughman RP (1990) The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 299:153\u2013157","journal-title":"Am J Med Sci"},{"key":"5481_CR19","first-page":"146","volume":"13","author":"G Pia","year":"1996","unstructured":"Pia G, Pascalis L, Aresu G, Rosetti L, Ledda MA (1996) Evaluation of the efficacy and toxicity of the cyclosporine A-flucortolone-methotrexate combination in the treatment of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 13:146\u2013152","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"5481_CR20","first-page":"34","volume":"283","author":"V Gavrysyuk","year":"2018","unstructured":"Gavrysyuk V, Merenkova E, Gumeniuk G, Gumeniuk M, Dziublyk Y (2018) Effectiveness and safety of methotrexate monotherapy in patients with pulmonary sarcoidosis. Georgian Med News 283:34\u201338","journal-title":"Georgian Med News"},{"key":"5481_CR21","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.2169\/internalmedicine.52.0976","volume":"52","author":"T Isshiki","year":"2013","unstructured":"Isshiki T et al (2013) Usefulness of low-dose methotrexate monotherapy for treating sarcoidosis. Intern Med 52:2727\u20132732","journal-title":"Intern Med"},{"key":"5481_CR22","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/00063198-200209000-00022","volume":"8","author":"VM Vucinic","year":"2002","unstructured":"Vucinic VM (2002) What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med 8:470\u2013476","journal-title":"Curr Opin Pulm Med"},{"key":"5481_CR23","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04314193?term=methotrexate&cond=sarcoidosis&draw=2&rank=1"},{"key":"5481_CR24","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1172\/JCI112088","volume":"76","author":"BA Chabner","year":"1985","unstructured":"Chabner BA et al (1985) Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 76:907\u2013912","journal-title":"J Clin Invest"},{"key":"5481_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/s13075-015-0814-z","volume":"17","author":"AF Hawwa","year":"2015","unstructured":"Hawwa AF, AlBawab A, Rooney M, Wedderburn LR, Beresford MW, McElnay JC (2015) Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study. Arthritis Res Ther 17:295","journal-title":"Arthritis Res Ther"},{"key":"5481_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","volume":"6","author":"ES Chan","year":"2010","unstructured":"Chan ES, Cronstein BN (2010) Methotrexate\u2014how does it really work? Nat Rev Rheumatol 6:175\u2013178","journal-title":"Nat Rev Rheumatol"},{"key":"5481_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/B978-0-12-800223-0.00004-9","volume":"73","author":"Z Hou","year":"2014","unstructured":"Hou Z, Matherly LH (2014) Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr Top Membr 73:175\u2013204","journal-title":"Curr Top Membr"},{"issue":"Suppl 2","key":"5481_CR28","first-page":"S87","volume":"25","author":"J Neradil","year":"2012","unstructured":"Neradil J, Pavlasova G, Veselska R (2012) New mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of methotrexate in cancer cells. Klin Onkol 25(Suppl 2):S87\u2013S92","journal-title":"Klin Onkol"},{"key":"5481_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.drup.2006.09.001","volume":"9","author":"YG Assaraf","year":"2006","unstructured":"Assaraf YG (2006) The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 9:227\u2013246","journal-title":"Drug Resist Updat"},{"key":"5481_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S1570-9639(03)00043-8","volume":"1647","author":"RN Appaji","year":"2003","unstructured":"Appaji RN, Ambili M, Jala VR, Subramanya HS, Savithri HS (2003) Structure-function relationship in serine hydroxymethyltransferase. Biochim Biophys Acta 1647:24\u201329","journal-title":"Biochim Biophys Acta"},{"key":"5481_CR31","unstructured":"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/methyl-tetrahydrofolate. Accessed 22 Feb 2019."},{"key":"5481_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/ar3871","author":"LK Stamp","year":"2012","unstructured":"Stamp LK, Hazlett J, Roberts RL, Frampton C, Highton J, Hessian PA (2012) Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. Arthritis Res Ther. https:\/\/doi.org\/10.1186\/ar3871","journal-title":"Arthritis Res Ther"},{"key":"5481_CR33","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0898-6568(03)00058-5","volume":"15","author":"G Schulte","year":"2003","unstructured":"Schulte G, Fredholm BB (2003) Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal 15:813\u2013827","journal-title":"Cell Signal"},{"key":"5481_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fimmu.2013.00085","volume":"4","author":"G Hask\u00f3","year":"2013","unstructured":"Hask\u00f3 G, Cronstein B (2013) Regulation of inflammation by adenosine. Front Immunol 4:85","journal-title":"Front Immunol"},{"key":"5481_CR35","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.bbamcr.2008.01.024","volume":"1783","author":"GG Yegutkin","year":"2008","unstructured":"Yegutkin GG (2008) Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta 1783:673\u2013694","journal-title":"Biochim Biophys Acta"},{"key":"5481_CR36","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/art.22643","volume":"56","author":"MC Montesinos","year":"2007","unstructured":"Montesinos MC, Takedachi M, Thompson LF, Wilder TF, Fern\u00e1ndez P, Cronstein BN (2007) The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient mice. Arthritis Rheum 56:1440\u20131445","journal-title":"Arthritis Rheum"},{"key":"5481_CR37","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/art.10712","volume":"48","author":"MC Montesinos","year":"2003","unstructured":"Montesinos MC et al (2003) Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 48:240\u2013247","journal-title":"Arthritis Rheum"},{"key":"5481_CR38","first-page":"433","volume":"25","author":"P Vergne","year":"1998","unstructured":"Vergne P et al (1998) Methotrexate and cyclooxygenase metabolism in cultured human rheumatoid synoviocytes. J Rheumatol 25:433\u2013440","journal-title":"J Rheumatol"},{"key":"5481_CR39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/rheumatology\/39.5.533","volume":"39","author":"SB Mello","year":"2000","unstructured":"Mello SB, Barros DM, Silva AS, Laurindo IM, Novaes GS (2000) Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis. Rheumatology (Oxford) 39:533\u2013536","journal-title":"Rheumatology (Oxford)"},{"key":"5481_CR40","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.1780350403","volume":"35","author":"RI Sperling","year":"1992","unstructured":"Sperling RI, Benincaso AI, Anderson RJ, Coblyn JS, Austen KF, Weinblatt ME (1992) Acute and chronic suppression of leukotriene B4 synthesis EX vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum 35:376\u2013384","journal-title":"Arthritis Rheum"},{"key":"5481_CR41","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/ar136","volume":"3","author":"W Van den Berg","year":"2001","unstructured":"Van den Berg W (2001) Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 3:18\u201326","journal-title":"Arthritis Res"},{"key":"5481_CR42","first-page":"1678","volume":"19","author":"DM Chang","year":"1992","unstructured":"Chang DM, Weinblatt ME, Schur PH (1992) The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis. J Rheumatol 19:1678\u20131682","journal-title":"J Rheumatol"},{"key":"5481_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/ar4444","author":"N Olsen","year":"2014","unstructured":"Olsen N, Spurlock C, Aune T (2014) Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. Arthritis Res Ther. https:\/\/doi.org\/10.1186\/ar4444","journal-title":"Arthritis Res Ther"},{"key":"5481_CR44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0162-3109(99)00185-X","volume":"47","author":"JY Sung","year":"2000","unstructured":"Sung JY et al (2000) Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis. Immunopharmacology 47:35\u201344","journal-title":"Immunopharmacology"},{"key":"5481_CR45","first-page":"89","volume":"64","author":"A Spadaro","year":"1997","unstructured":"Spadaro A, Taccari E, Riccieri V, Sensi F, Sili Scavalli A, Zoppini A (1997) Relationship of soluble interleukin-2-receptor and interleukin-6 with class-specific rheumatoid factors during low-dose methotrexate treatment in rheumatoid arthritis. Rev Rhum Engl Ed 64:89\u201394","journal-title":"Rev Rhum Engl Ed"},{"key":"5481_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/1529-0131(199801)41:1<48::AID-ART7>3.0.CO;2-K","volume":"41","author":"A Constantin","year":"1998","unstructured":"Constantin A et al (1998) Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum 41:48\u201357","journal-title":"Arthritis Rheum"},{"key":"5481_CR47","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/ar419","volume":"4","author":"ES Chan","year":"2002","unstructured":"Chan ES, Cronstein BN (2002) Molecular action of methotrexate in inflammatory diseases. Arthritis Res 4:266\u2013273","journal-title":"Arthritis Res"},{"key":"5481_CR48","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2165\/00003088-199630030-00002","volume":"30","author":"B Bannwarth","year":"1996","unstructured":"Bannwarth B, P\u00e9hourcq F, Schaeverbeke T, Dehais J (1996) Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 30:194\u2013210","journal-title":"Clin Pharmacokinet"},{"key":"5481_CR49","first-page":"S85","volume":"28","author":"O Morgacheva","year":"2010","unstructured":"Morgacheva O, Furst DE (2010) Use of MTX in the elderly and in patients with compromised renal function. Clin Exp Rheumatol 28:S85\u201394","journal-title":"Clin Exp Rheumatol"},{"key":"5481_CR50","first-page":"645","volume":"31","author":"M Hoekstra","year":"2004","unstructured":"Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M (2004) Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 31:645\u2013648","journal-title":"J Rheumatol"},{"key":"5481_CR51","first-page":"272","volume":"33","author":"S Goodman","year":"2015","unstructured":"Goodman S, Cronstein B, Bykerk V (2015) Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review. Clin Exp Rheumatol 33:272\u2013278","journal-title":"Clin Exp Rheumatol"},{"key":"5481_CR52","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/art.1780350603","volume":"35","author":"D Oguey","year":"1992","unstructured":"Oguey D, K\u00f6lliker F, Gerber NJ, Reichen J (1992) Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 35:611\u2013614","journal-title":"Arthritis Rheum"},{"key":"5481_CR53","first-page":"630","volume":"22","author":"RA Hamilton","year":"1995","unstructured":"Hamilton RA, Kremer JM (1995) The effects of food on methotrexate absorption. J Rheumatol 22:630\u2013632","journal-title":"J Rheumatol"},{"key":"5481_CR54","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/art.1780350708","volume":"35","author":"GD Kozloski","year":"1992","unstructured":"Kozloski GD, De Vito JM, Kisicki JC, Johnson JB (1992) The effect of food on the absorption of methotrexate sodium tablets in healthy volunteers. Arthritis Rheum 35:761\u2013764","journal-title":"Arthritis Rheum"},{"key":"5481_CR55","first-page":"1570","volume":"22","author":"LL Dupuis","year":"1995","unstructured":"Dupuis LL, Koren G, Silverman ED, Laxer RM (1995) Influence of food on the bioavailability of oral methotrexate in children. J Rheumatol 22:1570\u20131573","journal-title":"J Rheumatol"},{"key":"5481_CR56","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1002\/art.24685","volume":"60","author":"JE Baggott","year":"2009","unstructured":"Baggott JE, Morgan SL (2009) Methotrexate catabolism to 7-hydroxymethotrexate in rheumatoid arthritis alters drug efficacy and retention and is reduced by folic acid supplementation. Arthritis Rheum 60:2257\u20132261","journal-title":"Arthritis Rheum"},{"key":"5481_CR57","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/1529-0131(199808)41:8<1407::AID-ART9>3.0.CO;2-H","volume":"41","author":"JE Baggott","year":"1998","unstructured":"Baggott JE, Morgan SL, Koopman WJ (1998) The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and on urinary aminoimidazole carboxamide excretion. Arthritis Rheum 41:1407\u20131410","journal-title":"Arthritis Rheum"},{"key":"5481_CR58","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/rheumatology\/keg277","volume":"42","author":"RI Fox","year":"2003","unstructured":"Fox RI, Morgan SL, Smith HT, Robbins BA, Choc MG, Baggott JE (2003) Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone. Rheumatology (Oxford) 42:989\u2013994","journal-title":"Rheumatology (Oxford)"},{"key":"5481_CR59","first-page":"S27","volume":"28","author":"EN Van Roon","year":"2010","unstructured":"Van Roon EN, van de Laar MA (2010) Methotrexate bioavailability. Clin Exp Rheumatol 28:S27\u2013S32","journal-title":"Clin Exp Rheumatol"},{"key":"5481_CR60","first-page":"894","volume":"294","author":"BC Widemann","year":"2000","unstructured":"Widemann BC et al (2000) Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid. J Pharmacol Exp Ther 294:894\u2013901","journal-title":"J Pharmacol Exp Ther"},{"key":"5481_CR61","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/bcp.12209","volume":"77","author":"J Korell","year":"2014","unstructured":"Korell J et al (2014) Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell types. Br J Clin Pharmacol 77:493\u2013497","journal-title":"Br J Clin Pharmacol"},{"key":"5481_CR62","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/978-3-540-89615-9_15","volume":"193","author":"V Vallon","year":"2009","unstructured":"Vallon V, Osswald H (2009) Adenosine receptors and the kidney. Handb Exp Pharmacol 193:443\u2013470","journal-title":"Handb Exp Pharmacol"},{"key":"5481_CR63","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/BF00296253","volume":"19","author":"D Griffin","year":"1987","unstructured":"Griffin D, Said HM (1987) The enterohepatic circulation of methotrexate in vivo: inhibition by bile salt. Cancer Chemother Pharmacol 19:40\u201341","journal-title":"Cancer Chemother Pharmacol"},{"key":"5481_CR64","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/01480545.2016.1244680","volume":"40","author":"J Trifunovi\u0107","year":"2017","unstructured":"Trifunovi\u0107 J, Bor\u010di\u0107 V, Vukmirovi\u0107 S, Vasovi\u0107 V, Mikov M (2017) Bile acids and their oxo derivatives: environmentally safe materials for drug design and delivery. Drug Chem Toxicol 40:397\u2013405","journal-title":"Drug Chem Toxicol"},{"key":"5481_CR65","first-page":"1357","volume":"17","author":"Y Suda","year":"1990","unstructured":"Suda Y, Akazawa S (1990) Biliary and pancreatic excretion of methotrexate (MTX) and 5-FU on the MTX\/5-FU sequential therapy. Gan To Kagaku Ryoho 17:1357\u20131363","journal-title":"Gan To Kagaku Ryoho"},{"key":"5481_CR66","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.2298\/VSP170130046G","volume":"75","author":"S Golo\u010dorbin-Kon","year":"2018","unstructured":"Golo\u010dorbin-Kon S, Mikov M, Cveji\u0107 Hogervorst J, Al-Salami H, Maksimovi\u0107 V (2018) Dried blood spot: utilising dry blood for pharmacokinetic investigations\u2014an old method with great future for therapeutic drug monitoring. Vojnosanit Pregl 75:1222\u20131225","journal-title":"Vojnosanit Pregl"},{"key":"5481_CR67","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jpba.2009.04.025","volume":"50","author":"G Chen","year":"2009","unstructured":"Chen G, Fawcett JP, Mikov M, Tucker IG (2009) Simultaneous determination of methotrexate and its polyglutamate metabolites in Caco-2 cells by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 50:262\u2013266","journal-title":"J Pharm Biomed Anal"},{"key":"5481_CR68","doi-asserted-by":"crossref","unstructured":"Laketa J, Radovanovic M, Kojic T, Stojanovic G, Vukmirovic S, Mikov M, Stamenkovic Z (2017) Determination of electrical parameters of dried blood spot samples with different concentration of methotrexate. 2017 IEEE East-West Design & Test Symposium (EWDTS), Novi Sad. https:\/\/open.uns.ac.rs\/handle\/123456789\/9637","DOI":"10.1109\/EWDTS.2017.8110149"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-020-05481-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-020-05481-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-020-05481-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T23:56:29Z","timestamp":1621036589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-020-05481-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["5481"],"URL":"https:\/\/doi.org\/10.1007\/s11033-020-05481-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]},"assertion":[{"value":"21 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors have no conflicts of interest that are relevant to the content of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}